Denali Therapeutics
DNLI
108 hedge funds and large institutions have $1.23B invested in Denali Therapeutics in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 38 reducing their positions, and 19 closing their positions.
35% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $920K
13% more capital invested
Capital invested by funds: $1.09B → $1.23B (+$140M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.77% less ownership
Funds ownership: 74.56% → 73.79% (-0.77%)
8% less funds holding
Funds holding: 118 → 108 (-10)
21% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 38
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$9.99M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$6.62M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.78M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.05M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 3 |
Millennium Management
New York
|
-$1.56M |
| 4 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
-$1.21M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.1M |
DNLI Hedge Fund Activity: Q4 2019 in Review
108 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q4 2019, worth a combined $1.23B — up 13% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of DNLI and 14 opened new positions — a net loss of 5 holders — while 38 trimmed existing stakes and 30 added.
The largest buyer was Casdin Capital, adding an estimated $9.99M. The largest seller was Lord, Abbett & Co, cutting an estimated $15.6M.
- 108 institutional investors held Denali Therapeutics (DNLI) as of Q4 2019, down from 118 in Q3 2019.
- Funds reported $1.23B of Denali Therapeutics stock for Q4 2019, up 13% quarter-over-quarter.
- 14 funds opened new Denali Therapeutics positions in Q4 2019 and 19 closed out, a net change of -5 holders.
- The largest Denali Therapeutics buyer in Q4 2019 was Casdin Capital, an estimated $9.99M added.
- The largest Denali Therapeutics seller in Q4 2019 was Lord, Abbett & Co, an estimated $15.6M sold.
Based on aggregated 13F filings for Q4 2019.